La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !
CRISPR Therapeutics Gestione
Gestione criteri di controllo 3/4
CRISPR Therapeutics' Il CEO è Sam Kulkarni, nominato in Dec2017, e ha un mandato di 6.67 anni. la retribuzione annua totale è $ 12.32M, composta da 5.9% di stipendio e 94.1% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 0.35% delle azioni della società, per un valore di $ 14.74M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 4.8 anni e 5.2 anni.
Informazioni chiave
Sam Kulkarni
Amministratore delegato
US$12.3m
Compenso totale
| Percentuale dello stipendio del CEO | 5.9% |
| Mandato del CEO | 6.7yrs |
| Proprietà del CEO | 0.3% |
| Durata media del management | 4.8yrs |
| Durata media del Consiglio di amministrazione | 5.2yrs |
Aggiornamenti recenti sulla gestione
Recent updates
Crispr's Casgevy Launch: Promising Start, Uncertain Future
Aug 14A Look At The Intrinsic Value Of CRISPR Therapeutics AG (NASDAQ:CRSP)
Aug 09
Crispr Therapeutics Q2 Earnings: Casgevy Updates Underline 'Blockbuster' Potential
Aug 07Crispr Therapeutics Remains Expensive, With Slower Casgevy Monetization And Patent Battle
Jul 13Crispr Therapeutics: Beaten Down But Not Broken
Jul 07CRISPR Therapeutics AG's (NASDAQ:CRSP) Share Price Could Signal Some Risk
Jun 18Crispr Therapeutics, Futurism-Turning-Commercial, Defies 'Valuation' (Technical Analysis)
Jun 10Crispr Therapeutics' Strategic Moves Amidst Gene Therapy Challenges (Rating Upgrade)
Jun 03Shareholders Will Probably Hold Off On Increasing CRISPR Therapeutics AG's (NASDAQ:CRSP) CEO Compensation For The Time Being
May 23Newsflash: CRISPR Therapeutics AG (NASDAQ:CRSP) Analysts Have Been Trimming Their Revenue Forecasts
May 13We're Not Worried About CRISPR Therapeutics' (NASDAQ:CRSP) Cash Burn
May 10Crispr Therapeutics Q1 Earnings: Casgevy Launch Tip Of Gene Editing Iceberg
May 09Crispr Therapeutics: Market Misunderstanding Is Your Buying Opportunity (Upgrade)
May 03Crispr Therapeutics: Now Is The Time To Buy
Apr 24Calculating The Intrinsic Value Of CRISPR Therapeutics AG (NASDAQ:CRSP)
Apr 16Crispr Therapeutics: CASGEVY Commercial Launch Is Taking Shape
Mar 26There's Reason For Concern Over CRISPR Therapeutics AG's (NASDAQ:CRSP) Massive 26% Price Jump
Feb 22Crispr Therapeutics: Cautiously Optimistic
Feb 22Crispr Therapeutics: Investors Bet Against Casgevy Uptake
Feb 01Crispr Therapeutics: Commercial Validation Is The Next Step
Jan 18Impact Of Gene Therapies And Casgevy On Crispr AG And The Industry
Jan 11CRISPR Therapeutics AG's (NASDAQ:CRSP) Popularity With Investors Is Under Threat From Overpricing
Dec 25CRISPR Therapeutics (NASDAQ:CRSP) Is In A Good Position To Deliver On Growth Plans
Nov 02A Look At The Intrinsic Value Of CRISPR Therapeutics AG (NASDAQ:CRSP)
Oct 05CRISPR Therapeutics AG's (NASDAQ:CRSP) Business Is Yet to Catch Up With Its Share Price
Sep 14We're Not Very Worried About CRISPR Therapeutics' (NASDAQ:CRSP) Cash Burn Rate
Jul 24Calculating The Fair Value Of CRISPR Therapeutics AG (NASDAQ:CRSP)
Jun 28CRISPR Therapeutics (NASDAQ:CRSP) Is In A Good Position To Deliver On Growth Plans
Apr 02CRISPR Therapeutics AG's (NASDAQ:CRSP) Intrinsic Value Is Potentially 34% Above Its Share Price
Mar 06Companies Like CRISPR Therapeutics (NASDAQ:CRSP) Are In A Position To Invest In Growth
Dec 08CRISPR CAR T cell therapy for skin/blood cancer gets FDA regenerative medicine tag
Sep 28Crispr: Elucidating And Forecasting Key Developments
Sep 21Crispr Therapeutics: Nearing Harvest Season
Sep 08Crispr Therapeutics: Unlikely To Fall To May Lows, But Not The Time To Buy Yet (Technical Analysis)
Aug 25News Flash: Analysts Just Made A Noticeable Upgrade To Their CRISPR Therapeutics AG (NASDAQ:CRSP) Forecasts
Aug 09Analisi delle retribuzioni degli amministratori delegati
| Data | Compenso totale | Stipendio | Guadagni aziendali |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -US$266m |
| Mar 31 2024 | n/a | n/a | -US$217m |
| Dec 31 2023 | US$12m | US$725k | -US$154m |
| Sep 30 2023 | n/a | n/a | -US$354m |
| Jun 30 2023 | n/a | n/a | -US$416m |
| Mar 31 2023 | n/a | n/a | -US$524m |
| Dec 31 2022 | US$21m | US$700k | -US$650m |
| Sep 30 2022 | n/a | n/a | -US$681m |
| Jun 30 2022 | n/a | n/a | -US$633m |
| Mar 31 2022 | n/a | n/a | US$312m |
| Dec 31 2021 | US$17m | US$670k | US$378m |
| Sep 30 2021 | n/a | n/a | US$412m |
| Jun 30 2021 | n/a | n/a | US$447m |
| Mar 31 2021 | n/a | n/a | -US$392m |
| Dec 31 2020 | US$9m | US$625k | -US$349m |
| Sep 30 2020 | n/a | n/a | -US$211m |
| Jun 30 2020 | n/a | n/a | US$20m |
| Mar 31 2020 | n/a | n/a | US$46m |
| Dec 31 2019 | US$16m | US$550k | US$67m |
| Sep 30 2019 | n/a | n/a | -US$11m |
| Jun 30 2019 | n/a | n/a | -US$200m |
| Mar 31 2019 | n/a | n/a | -US$185m |
| Dec 31 2018 | US$10m | US$518k | -US$165m |
| Sep 30 2018 | n/a | n/a | -US$117m |
| Jun 30 2018 | n/a | n/a | -US$91m |
| Mar 31 2018 | n/a | n/a | -US$75m |
| Dec 31 2017 | US$7m | US$405k | -US$68m |
Compensazione vs Mercato: La retribuzione totale di Sam ($USD 12.32M ) è superiore alla media delle aziende di dimensioni simili nel mercato US ($USD 6.76M ).
Compensazione vs guadagni: La retribuzione di Sam è stata coerente con le performance aziendali dell'ultimo anno.
AMMINISTRATORE DELEGATO
Sam Kulkarni (46 yo)
6.7yrs
Mandato
US$12,322,196
Compensazione
Dr. Samarth Kulkarni, Ph D., also known as Sam, has been an Independent Director of Repare Therapeutics Inc. since November 2019. Dr. Kulkarni serves as an Independent Non-Executive Director of Centessa Ph...
Gruppo dirigente
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| CEO & Chairman | 6.7yrs | US$12.32m | 0.35% $ 15.4m | |
| Chief Financial Officer | 1.4yrs | US$5.91m | 0.011% $ 498.4k | |
| General Counsel & Secretary | 7.3yrs | US$3.51m | 0.069% $ 3.0m | |
| Founder | no data | Nessun dato | Nessun dato | |
| Co-Founder & Scientific Advisory Board Member | no data | Nessun dato | Nessun dato | |
| Scientific Founder & Advisory Board Member | no data | Nessun dato | Nessun dato | |
| Scientific Founder | no data | Nessun dato | Nessun dato | |
| Scientific Founder & Advisory Board Member | no data | Nessun dato | Nessun dato | |
| Scientific Founder & Advisory Board Member | no data | Nessun dato | Nessun dato | |
| Chief Operating Officer | less than a year | Nessun dato | 0.016% $ 689.4k | |
| Head of Technical Operations | 4.8yrs | Nessun dato | Nessun dato | |
| Vice President of Corporate Communications & Investor Relations | no data | Nessun dato | Nessun dato |
4.8yrs
Durata media
49yo
Età media
Gestione esperta: Il team dirigenziale di CRSP è considerato esperto (durata media dell'incarico 4.8 anni).
Membri del Consiglio di amministrazione
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| CEO & Chairman | 6.2yrs | US$12.32m | 0.35% $ 15.4m | |
| Co-Founder & Scientific Advisory Board Member | no data | Nessun dato | Nessun dato | |
| Scientific Founder & Advisory Board Member | no data | Nessun dato | Nessun dato | |
| Scientific Founder & Advisory Board Member | no data | Nessun dato | Nessun dato | |
| Scientific Founder & Advisory Board Member | no data | Nessun dato | Nessun dato | |
| Lead Independent Director | 4.2yrs | US$552.56k | 0.0023% $ 99.7k | |
| Independent Director | 9.3yrs | US$545.06k | 0.00031% $ 13.7k | |
| Independent Director | 5.2yrs | US$532.56k | 0% $ 0 | |
| Independent Director | 9.3yrs | US$542.56k | 0% $ 0 | |
| Member of Scientific Advisory Board | no data | Nessun dato | Nessun dato | |
| Independent Director | 5.2yrs | US$555.06k | 0% $ 0 | |
| Independent Director | 3.2yrs | US$536.24k | 0% $ 0 |
5.2yrs
Durata media
58yo
Età media
Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di CRSP sono considerati esperti (durata media dell'incarico 5.2 anni).